Precision subclassification of type 2 diabetes: a systematic review

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,01 MB, PDF-dokument

  • Shivani Misra
  • Robert Wagner
  • Bige Ozkan
  • Martin Schön
  • Magdalena Sevilla-Gonzalez
  • Katsiaryna Prystupa
  • Caroline C Wang
  • Raymond J Kreienkamp
  • Sara J Cromer
  • Mary R Rooney
  • Daisy Duan
  • Thuesen, Anne Cathrine Baun
  • Amelia S Wallace
  • Aaron Leong
  • Aaron J Deutsch
  • Lepola, Mette Andersen
  • Liana K Billings
  • Robert H Eckel
  • Wayne Huey-Herng Sheu
  • Hansen, Torben
  • Norbert Stefan
  • Mark O Goodarzi
  • Debashree Ray
  • Elizabeth Selvin
  • Jose C Florez
  • James B Meigs
  • Miriam S Udler
  • ADA/EASD PMDI
Background Heterogeneity in type 2 diabetes presentation and progression suggests that precision medicine interventions could improve clinical outcomes. We undertook a systematic review to determine whether strategies to subclassify type 2 diabetes were associated with high quality evidence, reproducible results and improved outcomes for patients.

Methods We searched PubMed and Embase for publications that used ‘simple subclassification’ approaches using simple categorisation of clinical characteristics, or ‘complex subclassification’ approaches which used machine learning or ‘omics approaches in people with established type 2 diabetes. We excluded other diabetes subtypes and those predicting incident type 2 diabetes. We assessed quality, reproducibility and clinical relevance of extracted full-text articles and qualitatively synthesised a summary of subclassification approaches.

Results Here we show data from 51 studies that demonstrate many simple stratification approaches, but none have been replicated and many are not associated with meaningful clinical outcomes. Complex stratification was reviewed in 62 studies and produced reproducible subtypes of type 2 diabetes that are associated with outcomes. Both approaches require a higher grade of evidence but support the premise that type 2 diabetes can be subclassified into clinically meaningful subtypes.

Conclusion Critical next steps toward clinical implementation are to test whether subtypes exist in more diverse ancestries and whether tailoring interventions to subtypes will improve outcomes.
OriginalsprogEngelsk
Artikelnummer138
TidsskriftCommunications Medicine
Vol/bind3
Antal sider19
ISSN2730-664X
DOI
StatusUdgivet - 2023

Bibliografisk note

© 2023. Springer Nature Limited.

ID: 379656931